Download Alsace BioValley

Alsace BioValley
CNS  Oncology  Immunology
DELEGATE(S)
Fabien Sebille, Project Manager
Mona Boye
9 Bd Gonthier d'Andernach
67400 Illkirch
France
www.alsacebiovalley.com/fr/Homepage-186.html
Incorporated: 1998
Employees:
18
Ownership:
Private
MISSION/BACKGROUND
At Alsace Biovalley, we will represent a selection of innovative companies from our cluster:
UROLEAD has developed a unique platform of in vivo screening models in onco-urology
using FRESH tumours xenografted and maintained in nude mice (32 kidney, 6 bladder and
5 prostate cancer models). They can assess the anti-cancer efficiency of drug candidates
with the possibility to identify predictive biomarkers associated to the treatment. More
information at www.urolead.com.
INNOVATIVE HEALTH DIAGNOSTICS (IHD) has developed innovative blood diagnostic for
Alzheimer’s disease, making IHD one of the leader in the field. The technology is based on
the detection of specific blood biomarkers (PKC and Abeta42 peptide) allowing a unique, non-invasive method of in vivo efficacy
evaluation of candidates targeting the amyloid pathway. The tests are especially adapted for longitudinal studies, as very small blood
samples are required. More information at www.ihdiag.com.
TRANSGENE: fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to
treat cancers and chronic infectious diseases.
They have particular interests in the following areas:
Innovative vaccine technologies and anti-viral compounds (HCV, HBV, TB)
Early stage therapeutic monoclonal antibodies for Cancer (HCC, colorectal, H&N…) or infectious diseases (HCV, HBV, TB)
Immunomodulatory strategies to boost IL12 response
www.transgene.fr
RHENOVIA PHARMA is the leader of Biosimulation technologies in the CNS field and provides access to the first platform modeling a
network of Glu/GABA synapses. This cutting edge technology can be applied to candidate profiling, side effects identification as well as
screening of synergistic drug combinations leading to extended patent life.
www.rhenovia.com
TECHNOLOGY
We will also present the latest out-licensing opportunities arising from academic research, gathered by CONECTUS, the unified
Technology Transfer Office in Alsace (2 Universities, University Hospital, engineering schools, INSERM and CNRS labs):
•New family of KIT/FLT3 kinases inhibitors with demonstrated in vivo efficacy and no signs of lung metastases commonly observed with
SOC.
•Dual HDAC/DNMT inhibitors
•Peptidic antagonist of Neuropilin1 for angiogenesis inhibition
•NCEs targeting CD13 (AP-N) for angiogenesis inhibition •Cardioprotective compounds against chemotherapies-induced toxicity
•Beta2A receptor agonist for treatment of neuropathic pain
•PPARa agonist for treatment of depression
•DIS inhibitor against HIV1 (first in class)
ALLIANCES
Alsace BioValley is the french partner of BioValley, a leading trinational biocluster in Europe spreading over Alsace-France, South BadenGermany, and Basel area-Switzerland.
Company Profiles – 8